US Stock MarketDetailed Quotes
CNTB Connect Biopharma
- 1.1300
- -0.0552-4.66%
Close Nov 7 16:00 ET
- 1.1300
- 0.00000.00%
Post 16:05 ET
62.27MMarket Cap-2897P/E (TTM)
1.1700High1.1100Low3.14KVolume1.1300Open1.1852Pre Close3.54KTurnover0.02%Turnover RatioLossP/E (Static)55.10MShares2.840052wk High0.56P/B16.54MFloat Cap0.677752wk Low--Dividend TTM14.64MShs Float29.2735Historical High--Div YieldTTM5.06%Amplitude0.5347Historical Low1.1300Avg Price1Lot Size
Connect Biopharma Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | |||||
| Gross profit | |||||
| Operating expense | -44.34%64.85M | 20.66%116.51M | 229.15%96.56M | 81.18%29.34M | 16.19M |
| Selling and administrative expenses | -30.24%14.52M | 9.42%20.81M | 160.32%19.01M | 426.16%7.3M | --1.39M |
| -General and administrative expense | -30.24%14.52M | 9.42%20.81M | 160.32%19.01M | 426.16%7.3M | --1.39M |
| Research and development costs | -46.28%51.91M | 20.04%96.63M | 248.44%80.5M | 51.90%23.1M | --15.21M |
| Other operating expenses | -70.08%-1.58M | 68.51%-929K | -175.77%-2.95M | -163.92%-1.07M | ---405.33K |
| Operating profit | 44.34%-64.85M | -20.66%-116.51M | -229.15%-96.56M | -81.18%-29.34M | -16.19M |
| Net non-operating interest income expense | 76.69%2.69M | 1,592.22%1.52M | 127.02%90K | -330.05%-333.06K | 144.78K |
| Non-operating interest income | 75.78%2.71M | 1,491.75%1.54M | -11.61%97K | -27.97%109.75K | --152.36K |
| Non-operating interest expense | 9.52%23K | 200.00%21K | 8.89%7K | -15.13%6.43K | --7.57K |
| Total other finance cost | ---- | ---- | ---- | --436.38K | ---- |
| Other net income (expense) | 198.75%2.77M | 97.34%-2.81M | -17.78%-105.53M | -1,012.60%-89.6M | -8.05M |
| Gain on sale of security | 65.32%2.88M | 101.67%1.74M | -16.55%-104.43M | -1,012.60%-89.6M | ---8.05M |
| Special income (charges) | --0 | ---4.7M | --0 | --0 | ---- |
| -Less:Impairment of capital assets | --0 | --4.7M | --0 | --0 | ---- |
| Other non- operating income (expenses) | -167.33%-101K | 113.65%150K | ---1.1M | ---- | ---- |
| Income before tax | 49.59%-59.38M | 41.69%-117.79M | -69.36%-202M | -394.89%-119.27M | -24.1M |
| Income tax | -59.73%120K | 12.03%298K | 266K | 0 | 0 |
| Net income | 49.61%-59.5M | 41.62%-118.09M | -69.59%-202.27M | -394.89%-119.27M | -24.1M |
| Net income continuous Operations | 49.61%-59.5M | 41.62%-118.09M | -69.59%-202.27M | -394.89%-119.27M | ---24.1M |
| Minority interest income | |||||
| Net income attributable to the parent company | 49.61%-59.5M | 41.62%-118.09M | -69.59%-202.27M | -394.89%-119.27M | -24.1M |
| Preferred stock dividends | |||||
| Other preferred stock dividends | |||||
| Net income attributable to common stockholders | 49.61%-59.5M | 41.62%-118.09M | -69.59%-202.27M | -394.89%-119.27M | -24.1M |
| Basic earnings per share | 49.77%-1.08 | 44.59%-2.15 | -75.48%-3.88 | -412.09%-2.2111 | -0.4318 |
| Diluted earnings per share | 49.77%-1.08 | 44.59%-2.15 | -75.48%-3.88 | -412.09%-2.2111 | -0.4318 |
| Dividend per share | |||||
| Currency Unit | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data